1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €10.36 (+2,366.67%). The median is €10.36 (+2,366.67%).
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0 | 100.00% |
| Gross profit | 0 | 100.00% |
| Net profit | -604.58K | 312.72% |
| EBITDA | -619.48K | 345.84% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €1.5M |
Number of shares | 3.29M |
52-week high/low | €0.84 - €0.13 |
| Dividends | No |
Beta | -0.17 |
P/E ratio | -0.62 |
PEG ratio | 0.00 |
P/B ratio | 3.06 |
P/S ratio | 0.00 |
Company profile
| Name | Avenue Therapeutics Aktie |
| CEO | Alexandra MacLean |
| Employees | 1 |
Discover assets
Shareholders of Avenue Therapeutics Aktie also invest in the following assets
